At the Extraordinary General Meeting of Infant Bacterial Therapeutics AB (publ) on June 9, 2023, it was resolved to approve…
Ongoing Phase 1b Dose-Escalation Study of Single-Agent Treatment with RVU120 in Patients with AML or High-Risk MDS Shows Clinical Benefit and…
Media ReleaseCOPENHAGEN, Denmark; June 9, 2023, at 9:00am CEST Results from phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab in combination…
EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant…
A single dose of KT-253 drives tumor regression and demonstrates differentiated pharmacology compared to small molecule inhibitor (SMI) in preclinical…
Collaboration brings together Quell’s proprietary multi-modular T-regulatory (Treg) cell engineering and manufacturing expertise with AstraZeneca’s proven development and commercial capabilities…
FREMONT, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Chronus Health, Inc., a disruptor in point-of-care diagnostics, today announced it has…
The studies also showed 18-40% lower costs incurred from ER visits and hospitalizations after 1 year for PAP-adherent OSA patients…
SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic…
Dallas, Texas, June 08, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing,…